Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Sexual dysfunction in the peri- and postmenopause. Status of incidence, pharmacological treatment and possible risks. A secondary publication

Research output: Contribution to journalReviewResearchpeer-review

  1. Injuries Related to the Use of Electric Scooters in a Danish Emergency Department - a Descriptive Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Effect and safety of endoscopic sleeve gastroplasty for treatning obesity - a systematic review

    Research output: Contribution to journalReviewResearchpeer-review

  3. Danish norms for the Strengths and Difficulties Questionnaire

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. A nationwide study of the quality of surgical guidelines and written patient information

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Prevalence of sarcopenia in a Danish geriatric out-patient population

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hyperseksualitet

    Research output: Contribution to journalJournal articleCommunication

  2. Sexual Health and Dysfunction in Patients With Rheumatoid Arthritis: A Cross-sectional Single-Center Study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

The frequency of female sexual dysfunction increases with age, and the menopausal transition has a negative effect on the sexuality. Pharmacological treatment options for female sexual dysfunction during the peri- and post-menopause include hormone therapy or sildenafil. A limited number of randomized, controlled trials have been conducted and evidence suggests that systemic hormone therapy with estrogen, estrogen/progesterone, estrogen/testosterone and tibolone have a positive impact on sexual dysfunction during the peri- and postmenopause. Further, there is evidence that treatment with local estrogen relieves vaginal dryness and dyspareunia. Recent knowledge on side effects related to hormone therapy necessitates careful evaluation of the indication for hormone therapy and the duration of postmenopausal hormone therapy should be as short as possible. Long-term side effects of testosterone have not yet been fully investigated. A positive effect of sildenafil has been observed in a limited group of women; those with arousal problems but with no desire problems. The results suggest an intensified focus on new pharmaceutical products for the treatment of female sexual dysfunction in the postmenopause. For the time being the effect of testosterone therapy and tibolone on female sexual dysfunction is being investigated. Sexual dysfunction in women (Female Sexual Dysfunction, FSD) is multi-factorial and influenced by physiological, psychological, social and emotional factors. FSD is defined in four diagnostic groups: desire-, arousal-, orgasm- and pain problems. Recently, it has been suggested that the woman herself should assess the dysfunction as distressful to be diagnosed as having a sexual dysfunction [1]. There are only a limited number of well-conducted population surveys on the prevalence of FSD. Further, relatively few randomized, controlled trials of pharmacological treatment of FSD have been carried out.

Original languageEnglish
JournalDanish Medical Journal
Volume53
Issue number3
Pages (from-to)349-53
Number of pages5
ISSN2245-1919
Publication statusPublished - Aug 2006

    Research areas

  • 3',5'-Cyclic-GMP Phosphodiesterases/antagonists & inhibitors, Androgen Antagonists/therapeutic use, Estradiol/blood, Estrogen Replacement Therapy, Estrogens/administration & dosage, Female, Humans, Menopause/physiology, Middle Aged, Norpregnenes/therapeutic use, Perimenopause, Piperazines/therapeutic use, Purines, Sexual Dysfunction, Physiological/drug therapy, Sexual Dysfunctions, Psychological/drug therapy, Sildenafil Citrate, Sulfones, Testosterone/administration & dosage, Vagina/drug effects

ID: 55814435